TY - JOUR T1 - Consequences of COVID-19 vaccine allocation inequity in Chicago JF - medRxiv DO - 10.1101/2021.09.22.21263984 SP - 2021.09.22.21263984 AU - Sharon Zeng AU - Kenley M. Pelzer AU - Robert D. Gibbons AU - Monica E. Peek AU - William F. Parker Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/23/2021.09.22.21263984.abstract N2 - During Chicago’s initial COVID-19 vaccine rollout, the city disproportionately allocated vaccines to zip codes with high incomes and predominantly White populations. However, the impact of this inequitable distribution on COVID-19 outcomes is unknown. This observational study determined the association between zip-code level vaccination rate and COVID-19 mortality in residents of 52 Chicago zip codes. After controlling for age distribution and recovery from infection, a 10% higher vaccination rate by March 28, 2021, was associated with a 39% lower relative risk of death during the peak of the spring wave of COVID-19. Using a difference-in-difference analysis, Chicago could have prevented an estimated 72% of deaths in the least vaccinated quartile of the city (vaccination rates of 17.8 – 26.9%) if it had had the same vaccination rate as the most vaccinated quartile (39.9 – 49.3%). Inequitable vaccine allocation in Chicago likely exacerbated existing racial disparities in COVID-19 mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupport was provided by the National Institute on Aging to Sharon Zeng as part of the Pritzker Summer Research Program in Aging. William Parker was supported by the National Heart, Lung, and Blood Institute (K08 HL150291).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was a secondary analysis of publicly available, de-identified data and was granted exemption status by the University of Chicago Biological Sciences Division/University of Chicago Medical Center Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this manuscript was is publically available. https://github.com/zengsharon/ChicagoVaccineAllocation https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=covid-19 ER -